Natera (NTRA) Posts Quarterly Earnings Results, Misses Estimates By $0.03 EPS

Natera (NASDAQ:NTRA) announced its quarterly earnings results on Thursday. The medical research company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($0.03), Briefing.com reports. Natera had a negative net margin of 59.07% and a negative return on equity of 752.93%. The firm had revenue of $65.30 million during the quarter, compared to analyst estimates of $66.42 million. During the same period last year, the firm earned ($0.51) EPS. Natera’s quarterly revenue was up 16.8% on a year-over-year basis. Natera updated its FY 2018 guidance to EPS.

Shares of NTRA stock traded down $3.83 on Friday, hitting $16.80. The stock had a trading volume of 4,391,474 shares, compared to its average volume of 457,138. The firm has a market capitalization of $1.30 billion, a price-to-earnings ratio of -7.00 and a beta of 2.11. Natera has a twelve month low of $8.60 and a twelve month high of $29.62.

In related news, insider Jonathan Sheena sold 166,667 shares of the company’s stock in a transaction on Friday, September 14th. The shares were sold at an average price of $24.27, for a total value of $4,045,008.09. Following the completion of the transaction, the insider now directly owns 481,975 shares of the company’s stock, valued at approximately $11,697,533.25. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, COO Steven Leonard Chapman sold 35,000 shares of the company’s stock in a transaction on Friday, October 12th. The stock was sold at an average price of $20.66, for a total transaction of $723,100.00. Following the completion of the transaction, the chief operating officer now directly owns 24,240 shares of the company’s stock, valued at $500,798.40. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 2,014,988 shares of company stock valued at $48,674,710. Company insiders own 13.18% of the company’s stock.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Jennison Associates LLC boosted its stake in Natera by 39.1% in the 3rd quarter. Jennison Associates LLC now owns 3,641,848 shares of the medical research company’s stock worth $87,186,000 after purchasing an additional 1,024,225 shares during the period. BlackRock Inc. boosted its stake in Natera by 33.5% in the 3rd quarter. BlackRock Inc. now owns 2,785,208 shares of the medical research company’s stock worth $66,679,000 after purchasing an additional 698,379 shares during the period. FMR LLC acquired a new position in Natera in the 3rd quarter worth $59,599,000. Fred Alger Management Inc. acquired a new position in Natera in the 2nd quarter worth $33,271,000. Finally, Macquarie Group Ltd. boosted its stake in Natera by 9.0% in the 2nd quarter. Macquarie Group Ltd. now owns 1,714,886 shares of the medical research company’s stock worth $32,274,000 after purchasing an additional 141,278 shares during the period. 67.46% of the stock is owned by hedge funds and other institutional investors.

Several brokerages have recently issued reports on NTRA. Piper Jaffray Companies boosted their price target on shares of Natera to $27.00 and gave the company an “overweight” rating in a report on Thursday, August 9th. Cowen reissued a “buy” rating and issued a $30.00 price target on shares of Natera in a report on Friday. BidaskClub lowered shares of Natera from a “strong-buy” rating to a “buy” rating in a report on Thursday, August 30th. Zacks Investment Research lowered shares of Natera from a “hold” rating to a “sell” rating in a report on Wednesday, October 10th. Finally, TheStreet lowered shares of Natera from a “c-” rating to a “d+” rating in a report on Tuesday, October 9th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $28.25.

WARNING: This piece was first published by Community Financial News and is the property of of Community Financial News. If you are accessing this piece on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be accessed at https://www.com-unik.info/2018/11/10/natera-ntra-posts-quarterly-earnings-results-misses-estimates-by-0-03-eps.html.

Natera Company Profile

Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

Recommended Story: What is the yield curve?

Earnings History for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit